Skip to content
10-Q

Quarterly Report

LIGAND PHARMACEUTICALS INC LGND LGNDZ LGNXZ LGNYZ LGNZZ

0000886163-26-000034

← back to feed
Filed
May 8, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 5, 2026 20.04M sh
Shares Diluted Q1 2026 · Mar 31, 2026 19.88M sh
Shares Diluted Q1 2026 · Mar 31, 2025 19.19M sh
Capex Q1 2026 · Mar 31, 2026 $228K
Capex Q1 2026 · Mar 31, 2025 $214K
Operating Cash Flow Q1 2026 · Mar 31, 2026 $48.69M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$25.45M
Short Term Investments Q1 2026 · Mar 31, 2026 $664.33M
Short Term Investments Q1 2026 · Dec 31, 2025 $558.59M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $115.08M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $174.93M
Stockholders Equity Q1 2026 · Mar 31, 2026 $997.32M
Stockholders Equity Q1 2026 · Dec 31, 2025 $1.02B
Stockholders Equity restated Q1 2026 · Mar 31, 2025 $795.59M
Stockholders Equity Q1 2026 · Dec 31, 2024 $830.44M
Current Liabilities Q1 2026 · Mar 31, 2026 $40.67M
Current Liabilities Q1 2026 · Dec 31, 2025 $37.45M
Total Liabilities Q1 2026 · Mar 31, 2026 $534.78M
Total Liabilities Q1 2026 · Dec 31, 2025 $543.43M
Current Assets Q1 2026 · Mar 31, 2026 $865.42M
Current Assets Q1 2026 · Dec 31, 2025 $832.27M
Total Assets Q1 2026 · Mar 31, 2026 $1.53B
Total Assets Q1 2026 · Dec 31, 2025 $1.56B
Eps Diluted Q1 2026 · Mar 31, 2026 −$0.67
Eps Diluted Q1 2026 · Mar 31, 2025 −$2.21
Eps Basic Q1 2026 · Mar 31, 2026 −$0.67
Eps Basic Q1 2026 · Mar 31, 2025 −$2.21
Sga Expense Q1 2026 · Mar 31, 2026 $20.84M
Sga Expense Q1 2026 · Mar 31, 2025 $18.8M
Rd Expense Q1 2026 · Mar 31, 2026 $2.15M
Rd Expense Q1 2026 · Mar 31, 2025 $50.09M
Net Income Q1 2026 · Mar 31, 2026 −$13.35M
Net Income Q1 2026 · Mar 31, 2025 −$42.45M
Operating Income Q1 2026 · Mar 31, 2026 $17.37M
Operating Income Q1 2026 · Mar 31, 2025 −$36.22M
Revenue Q1 2026 · Mar 31, 2026 $51.72M
Revenue Q1 2026 · Mar 31, 2025 $45.33M